194 related articles for article (PubMed ID: 27156189)
21. Immunogenicity of bivalent types 1 and 3 oral poliovirus vaccine: a randomised, double-blind, controlled trial.
Sutter RW; John TJ; Jain H; Agarkhedkar S; Ramanan PV; Verma H; Deshpande J; Singh AP; Sreevatsava M; Malankar P; Burton A; Chatterjee A; Jafari H; Aylward RB
Lancet; 2010 Nov; 376(9753):1682-8. PubMed ID: 20980048
[TBL] [Abstract][Full Text] [Related]
22. Safety and immunogenicity of inactivated poliovirus vaccine when given with measles-rubella combined vaccine and yellow fever vaccine and when given via different administration routes: a phase 4, randomised, non-inferiority trial in The Gambia.
Clarke E; Saidu Y; Adetifa JU; Adigweme I; Hydara MB; Bashorun AO; Moneke-Anyanwoke N; Umesi A; Roberts E; Cham PM; Okoye ME; Brown KE; Niedrig M; Chowdhury PR; Clemens R; Bandyopadhyay AS; Mueller J; Jeffries DJ; Kampmann B
Lancet Glob Health; 2016 Aug; 4(8):e534-47. PubMed ID: 27364568
[TBL] [Abstract][Full Text] [Related]
23. Safety and immunogenicity of shorter interval schedules of the novel oral poliovirus vaccine type 2 in infants: a phase 3, randomised, controlled, non-inferiority study in the Dominican Republic.
Rivera Mejía L; Peña Méndez L; Bandyopadhyay AS; Gast C; Mazara S; Rodriguez K; Rosario N; Zhang Y; Mainou BA; Jimeno J; Aguirre G; Rüttimann R
Lancet Infect Dis; 2024 Mar; 24(3):275-284. PubMed ID: 38109921
[TBL] [Abstract][Full Text] [Related]
24. Monovalent type-1 oral poliovirus vaccine given at short intervals in Pakistan: a randomised controlled, four-arm, open-label, non-inferiority trial.
Mir F; Quadri F; Mach O; Ahmed I; Bhatti Z; Khan A; Rehman NU; Durry E; Salama M; Oberste SM; Weldon WC; Sutter RW; Zaidi AK
Lancet Infect Dis; 2015 Aug; 15(8):889-97. PubMed ID: 26093979
[TBL] [Abstract][Full Text] [Related]
25. Safety and immunogenicity of a parenteral P2-VP8-P[8] subunit rotavirus vaccine in toddlers and infants in South Africa: a randomised, double-blind, placebo-controlled trial.
Groome MJ; Koen A; Fix A; Page N; Jose L; Madhi SA; McNeal M; Dally L; Cho I; Power M; Flores J; Cryz S
Lancet Infect Dis; 2017 Aug; 17(8):843-853. PubMed ID: 28483414
[TBL] [Abstract][Full Text] [Related]
26. Immunogenicity and safety evaluation of bivalent types 1 and 3 oral poliovirus vaccine by comparing different poliomyelitis vaccination schedules in China: A randomized controlled non-inferiority clinical trial.
Qiu J; Yang Y; Huang L; Wang L; Jiang Z; Gong J; Wang W; Wang H; Guo S; Li C; Wei S; Mo Z; Xia J
Hum Vaccin Immunother; 2017 Jun; 13(6):1-10. PubMed ID: 28362135
[TBL] [Abstract][Full Text] [Related]
27. Zinc supplementation fails to increase the immunogenicity of oral poliovirus vaccine: a randomized controlled trial.
Habib MA; Soofi S; Sheraz A; Bhatti ZS; Okayasu H; Zaidi SZ; Molodecky NA; Pallansch MA; Sutter RW; Bhutta ZA
Vaccine; 2015 Feb; 33(6):819-25. PubMed ID: 25500307
[TBL] [Abstract][Full Text] [Related]
28. Monovalent type 1 oral poliovirus vaccine in newborns.
el-Sayed N; el-Gamal Y; Abbassy AA; Seoud I; Salama M; Kandeel A; Hossny E; Shawky A; Hussein HA; Pallansch MA; van der Avoort HG; Burton AH; Sreevatsava M; Malankar P; Wahdan MH; Sutter RW
N Engl J Med; 2008 Oct; 359(16):1655-65. PubMed ID: 18923170
[TBL] [Abstract][Full Text] [Related]
29. A measles and rubella vaccine microneedle patch in The Gambia: a phase 1/2, double-blind, double-dummy, randomised, active-controlled, age de-escalation trial.
Adigweme I; Yisa M; Ooko M; Akpalu E; Bruce A; Donkor S; Jarju LB; Danso B; Mendy A; Jeffries D; Segonds-Pichon A; Njie A; Crooke S; El-Badry E; Johnstone H; Royals M; Goodson JL; Prausnitz MR; McAllister DV; Rota PA; Henry S; Clarke E
Lancet; 2024 May; 403(10439):1879-1892. PubMed ID: 38697170
[TBL] [Abstract][Full Text] [Related]
30. The effect of probiotics and zinc supplementation on the immune response to oral rotavirus vaccine: A randomized, factorial design, placebo-controlled study among Indian infants.
Lazarus RP; John J; Shanmugasundaram E; Rajan AK; Thiagarajan S; Giri S; Babji S; Sarkar R; Kaliappan PS; Venugopal S; Praharaj I; Raman U; Paranjpe M; Grassly NC; Parker EPK; Parashar UD; Tate JE; Fleming JA; Steele AD; Muliyil J; Abraham AM; Kang G
Vaccine; 2018 Jan; 36(2):273-279. PubMed ID: 28874323
[TBL] [Abstract][Full Text] [Related]
31. Immunogenicity of sequential inactivated and oral poliovirus vaccines (OPV) versus inactivated poliovirus vaccine (IPV) alone in healthy infants: A systematic review and meta-analysis.
Tang G; Yin W; Cao Y; Tan L; Wu S; Cao Y; Fu X; Yan J; Jiang X
Hum Vaccin Immunother; 2018; 14(11):2636-2643. PubMed ID: 29985751
[TBL] [Abstract][Full Text] [Related]
32. Efficacy of a monovalent human-bovine (116E) rotavirus vaccine in Indian infants: a randomised, double-blind, placebo-controlled trial.
Bhandari N; Rongsen-Chandola T; Bavdekar A; John J; Antony K; Taneja S; Goyal N; Kawade A; Kang G; Rathore SS; Juvekar S; Muliyil J; Arya A; Shaikh H; Abraham V; Vrati S; Proschan M; Kohberger R; Thiry G; Glass R; Greenberg HB; Curlin G; Mohan K; Harshavardhan GV; Prasad S; Rao TS; Boslego J; Bhan MK;
Lancet; 2014 Jun; 383(9935):2136-43. PubMed ID: 24629994
[TBL] [Abstract][Full Text] [Related]
33. Community transmission of type 2 poliovirus after cessation of trivalent oral polio vaccine in Bangladesh: an open-label cluster-randomised trial and modelling study.
Taniuchi M; Famulare M; Zaman K; Uddin MJ; Upfill-Brown AM; Ahmed T; Saha P; Haque R; Bandyopadhyay AS; Modlin JF; Platts-Mills JA; Houpt ER; Yunus M; Petri WA
Lancet Infect Dis; 2017 Oct; 17(10):1069-1079. PubMed ID: 28693854
[TBL] [Abstract][Full Text] [Related]
34. Safety and immunogenicity of a two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Europe (EBOVAC2): a randomised, observer-blind, participant-blind, placebo-controlled, phase 2 trial.
Pollard AJ; Launay O; Lelievre JD; Lacabaratz C; Grande S; Goldstein N; Robinson C; Gaddah A; Bockstal V; Wiedemann A; Leyssen M; Luhn K; Richert L; Bétard C; Gibani MM; Clutterbuck EA; Snape MD; Levy Y; Douoguih M; Thiebaut R;
Lancet Infect Dis; 2021 Apr; 21(4):493-506. PubMed ID: 33217361
[TBL] [Abstract][Full Text] [Related]
35. Safety, immunogenicity and lot-to-lot consistency of a new Bivalent Oral Polio Vaccine (bOPV) in healthy Infants: Results of a Phase III, observer blind, randomized, controlled clinical study.
Zaman K; Kingma R; Yunus M; van Straaten I; Mekkes D; Bouwstra X; Gunale B; Kulkarni PS
Vaccine; 2019 Jul; 37(31):4275-4280. PubMed ID: 31235374
[TBL] [Abstract][Full Text] [Related]
36. Immunogenicity of novel oral poliovirus vaccine type 2 administered concomitantly with bivalent oral poliovirus vaccine: an open-label, non-inferiority, randomised, controlled trial.
Wilkinson AL; Zaman K; Hoque M; Estivariz CF; Burns CC; Konopka-Anstadt JL; Mainou BA; Kovacs SD; An Q; Lickness JS; Yunus M; Snider CJ; Zhang Y; Coffee E; Abid T; Wassilak SGF; Pallansch MA; Oberste MS; Vertefeuille JF; Anand A
Lancet Infect Dis; 2023 Sep; 23(9):1062-1071. PubMed ID: 37178706
[TBL] [Abstract][Full Text] [Related]
37. Immunogenicity of type 2 monovalent oral and inactivated poliovirus vaccines for type 2 poliovirus outbreak response: an open-label, randomised controlled trial.
Zaman K; Estívariz CF; Morales M; Yunus M; Snider CJ; Gary HE; Weldon WC; Oberste MS; Wassilak SG; Pallansch MA; Anand A
Lancet Infect Dis; 2018 Jun; 18(6):657-665. PubMed ID: 29571817
[TBL] [Abstract][Full Text] [Related]
38. Oral iodine supplementation does not reduce neutralizing antibody responses to oral poliovirus vaccine.
Taffs RE; Enterline JC; Rusmil K; Muhilal ; Suwardi SS; Rustama D; Djatnika ; Cobra C; Semba RD; Cohen N; Asher DM
Bull World Health Organ; 1999; 77(6):484-91. PubMed ID: 10427933
[TBL] [Abstract][Full Text] [Related]
39. Antirotavirus IgA seroconversion rates in children who receive concomitant oral poliovirus vaccine: A secondary, pooled analysis of Phase II and III trial data from 33 countries.
Baker JM; Tate JE; Leon J; Haber MJ; Lopman BA
PLoS Med; 2019 Dec; 16(12):e1003005. PubMed ID: 31887139
[TBL] [Abstract][Full Text] [Related]
40. Safety and immunogenicity of an investigational maternal trivalent group B streptococcus vaccine in healthy women and their infants: a randomised phase 1b/2 trial.
Madhi SA; Cutland CL; Jose L; Koen A; Govender N; Wittke F; Olugbosi M; Meulen AS; Baker S; Dull PM; Narasimhan V; Slobod K
Lancet Infect Dis; 2016 Aug; 16(8):923-34. PubMed ID: 27139805
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
